CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

GSK is taking to the airwaves to get the message out about respiratory syncytial virus (RSV), presenting a TV special about ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

In an import contrast to events in the USA, UK pharma major GSK late Thursday announced the approval of Blenrep (belantamab ...

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by the European Commission (EC) to treat adults with relapsed or refractory multiple myeloma.

The European Union has given regulatory approval to GSK's drug, Blenrep, for treating relapsed or treatment-resistant forms of blood plasma cell cancer.

(Alliance News) - GSK PLC on Thursday said its Blenrep blood cancer treatment has been approved in Europe, as it awaits a final decision from the US regulator. The London-based pharmaceutical firm ...

Shares of health coverage company Centene (NYSE:CNC) jumped 5.9% in the afternoon session after the company reported ...

Discover MarketSmith India's recommended stocks for 25 July. Get insights into top-performing stocks and make informed ...

Thinking-2507, as we'll call it for short, now leads or closely trails top-performing models across several major benchmarks.